Company intelligence / Profile preview
ChomiX Biotech
- Ownership
- Private
- Development stage
- Other
Overview
ChomiX Biotech is developing at least three preclinical oncology programs targeting tumor-related proteins (including membrane proteins and E3 ligases). Its platforms enable discovery of covalent binders and identification of novel targets in living cells, especially for "undruggable" proteins. ChomiX has numerous ongoing academic collaborations and has raised multi-million dollar pre-A+ financing to expand its capabilities.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on ChomiX Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChomiX Biotech.